NASDAQ:RLAY Relay Therapeutics - RLAY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.58 -0.05 (-0.32%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.38▼$16.4050-Day Range$15.33▼$22.7652-Week Range$12.65▼$35.36Volume694,652 shsAverage Volume1.02 million shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$31.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Relay Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside103.0% Upside$31.63 Price TargetShort InterestBearish21.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.13 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.01) to ($3.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.19 out of 5 starsMedical Sector958th out of 983 stocksBiological Products, Except Diagnostic Industry161st out of 163 stocks 3.3 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.63, Relay Therapeutics has a forecasted upside of 103.0% from its current price of $15.58.Amount of Analyst CoverageRelay Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.07% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 2.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 15 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,133,190.00 in company stock.Percentage Held by InsidersOnly 4.43% of the stock of Relay Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($3.01) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Relay Therapeutics (NASDAQ:RLAY) StockRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Stock News HeadlinesMarch 13, 2023 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives $32.14 Average PT from AnalystsMarch 6, 2023 | finance.yahoo.comRelay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACRMarch 22, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 1, 2023 | msn.comRelay Therapeutics's Return On Capital Employed OverviewFebruary 26, 2023 | finance.yahoo.comRelay Therapeutics Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagFebruary 23, 2023 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue EstimatesFebruary 23, 2023 | msn.comRelay Therapeutics GAAP EPS of -$0.56 beats by $0.14, revenue of $0.25M beats by $0.08MFebruary 22, 2023 | benzinga.comRelay Therapeutics Earnings PreviewMarch 22, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 16, 2023 | finance.yahoo.comRelay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate HighlightsFebruary 15, 2023 | seekingalpha.comRLAY Relay Therapeutics, Inc.February 7, 2023 | finance.yahoo.comOppenheimer Says These 2 Stocks Have Double-Digit Gains in SightFebruary 2, 2023 | finance.yahoo.comRelay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology DayFebruary 1, 2023 | nasdaq.comBlackRock Increases Position in Relay Therapeutics (RLAY)January 15, 2023 | nasdaq.comRelay Therapeutics (RLAY) Shares Cross Above 200 DMAJanuary 13, 2023 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?December 31, 2022 | finance.yahoo.comRelay Therapeutics, Inc.'s (NASDAQ:RLAY) Intrinsic Value Is Potentially 23% Below Its Share PriceNovember 30, 2022 | msn.comRelay Therapeutics: No. 1 on the list of large employers in Massachusetts for 2022November 24, 2022 | finance.yahoo.comWill Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?November 7, 2022 | markets.businessinsider.comWhere Relay Therapeutics Stands With AnalystsNovember 3, 2022 | finance.yahoo.comRelay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate HighlightsNovember 3, 2022 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue EstimatesNovember 2, 2022 | msn.comRelay Therapeutics's Earnings OutlookOctober 14, 2022 | finance.yahoo.comRelay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 11% this week, taking one-year losses to 44%September 30, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Relay TherapeuticsSeptember 30, 2022 | markets.businessinsider.comExpert Ratings for Relay TherapeuticsSeptember 26, 2022 | nasdaq.comRelay Therapeutics Breaks Above 200-Day Moving Average - Bullish for RLAYSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Company Calendar Last Earnings2/23/2023Today3/22/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees245Year FoundedN/APrice Target and Rating Average Stock Price Forecast$31.63 High Stock Price Forecast$46.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+103.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,510,000.00 Net Margins-21,036.13% Pretax Margin-21,036.13% Return on Equity-33.05% Return on Assets-28.74% Debt Debt-to-Equity RatioN/A Current Ratio16.00 Quick Ratio16.00 Sales & Book Value Annual Sales$1.38 million Price / Sales1,370.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.86 per share Price / Book1.98Miscellaneous Outstanding Shares121,390,000Free Float116,008,000Market Cap$1.89 billion OptionableNot Optionable Beta1.32 Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Co-Founder & Independent Chairman Comp: $105kDr. Sanjiv K. Patel M.A. (Age 49)M.B.A., M.D., MBBS, CEO, Pres & Director Comp: $1.02MDr. Mark Murcko Ph.D. (Age 63)Co-Founder & Director Comp: $65.75kMr. Thomas Catinazzo (Age 46)Chief Financial Officer Comp: $558.69kMr. Andy PorterChief Admin. OfficerMr. Brian R. Adams J.D. (Age 49)Chief Legal Officer & Sec. Comp: $612.05kDr. Donald A. Bergstrom M.D. (Age 51)Ph.D., Pres of R&D Comp: $722.26kMr. Peter RahmerSr. VP of Corp. Affairs & Investor RelationsDr. Deborah Palestrant Ph.D.VP of Corp. Devel. & StrategyMr. Jim Watters Ph.D.Sr. VP & Head of Late ResearchMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTSpringWorks TherapeuticsNASDAQ:SWTXRevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCBought 3,214 shares on 2/28/2023Ownership: 0.084%Alliancebernstein L.P.Bought 286,596 shares on 2/16/2023Ownership: 1.398%Legal & General Group PlcSold 883 shares on 2/15/2023Ownership: 0.052%Capital Impact Advisors LLCBought 1,125 shares on 2/15/2023Ownership: 0.014%Metropolitan Life Insurance Co NYBought 706 shares on 2/15/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RLAY Stock - Frequently Asked Questions Should I buy or sell Relay Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLAY shares. View RLAY analyst ratings or view top-rated stocks. What is Relay Therapeutics' stock price forecast for 2023? 7 brokers have issued 1 year price objectives for Relay Therapeutics' shares. Their RLAY share price forecasts range from $13.00 to $46.00. On average, they predict the company's share price to reach $31.63 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price. View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts. How have RLAY shares performed in 2023? Relay Therapeutics' stock was trading at $14.94 at the beginning of the year. Since then, RLAY shares have increased by 4.3% and is now trading at $15.58. View the best growth stocks for 2023 here. When is Relay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our RLAY earnings forecast. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) released its quarterly earnings results on Thursday, February, 23rd. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.12. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $0.18 million. Relay Therapeutics had a negative trailing twelve-month return on equity of 33.05% and a negative net margin of 21,036.13%. The business's revenue for the quarter was down 55.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.36 earnings per share. What ETFs hold Relay Therapeutics' stock? ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), First Trust NASDAQ BuyWrite Income ETF (FTQI), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC). When did Relay Therapeutics IPO? (RLAY) raised $250 million in an initial public offering on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO. What is Relay Therapeutics' stock symbol? Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY." Who are Relay Therapeutics' major shareholders? Relay Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.72%), JPMorgan Chase & Co. (3.70%), ArrowMark Colorado Holdings LLC (2.22%), Morgan Stanley (1.96%), T. Rowe Price Investment Management Inc. (1.66%) and Norges Bank (1.48%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Rock Ventures Iii LP Third, Sanjiv Patel and Thomas Catinazzo. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Relay Therapeutics' stock price today? One share of RLAY stock can currently be purchased for approximately $15.58. How much money does Relay Therapeutics make? Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.89 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. How many employees does Relay Therapeutics have? The company employs 245 workers across the globe. How can I contact Relay Therapeutics? Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com. This page (NASDAQ:RLAY) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.